Cargando…
Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
[Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015217/ https://www.ncbi.nlm.nih.gov/pubmed/33095554 http://dx.doi.org/10.1021/acscombsci.0c00099 |
_version_ | 1783673636774739968 |
---|---|
author | Ashrafizadeh, Milad Zarrabi, Ali Hushmandi, Kiavash Hashemi, Farid Rahmani Moghadam, Ebrahim Raei, Mehdi Kalantari, Mahshad Tavakol, Shima Mohammadinejad, Reza Najafi, Masoud Tay, Franklin R. Makvandi, Pooyan |
author_facet | Ashrafizadeh, Milad Zarrabi, Ali Hushmandi, Kiavash Hashemi, Farid Rahmani Moghadam, Ebrahim Raei, Mehdi Kalantari, Mahshad Tavakol, Shima Mohammadinejad, Reza Najafi, Masoud Tay, Franklin R. Makvandi, Pooyan |
author_sort | Ashrafizadeh, Milad |
collection | PubMed |
description | [Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research. |
format | Online Article Text |
id | pubmed-8015217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-80152172021-04-02 Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy Ashrafizadeh, Milad Zarrabi, Ali Hushmandi, Kiavash Hashemi, Farid Rahmani Moghadam, Ebrahim Raei, Mehdi Kalantari, Mahshad Tavakol, Shima Mohammadinejad, Reza Najafi, Masoud Tay, Franklin R. Makvandi, Pooyan ACS Comb Sci [Image: see text] Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, co-delivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research. American Chemical Society 2020-10-23 2020-12-14 /pmc/articles/PMC8015217/ /pubmed/33095554 http://dx.doi.org/10.1021/acscombsci.0c00099 Text en © 2020 American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Ashrafizadeh, Milad Zarrabi, Ali Hushmandi, Kiavash Hashemi, Farid Rahmani Moghadam, Ebrahim Raei, Mehdi Kalantari, Mahshad Tavakol, Shima Mohammadinejad, Reza Najafi, Masoud Tay, Franklin R. Makvandi, Pooyan Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy |
title | Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer
Therapy |
title_full | Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer
Therapy |
title_fullStr | Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer
Therapy |
title_full_unstemmed | Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer
Therapy |
title_short | Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer
Therapy |
title_sort | progress in natural compounds/sirna co-delivery employing nanovehicles for cancer
therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015217/ https://www.ncbi.nlm.nih.gov/pubmed/33095554 http://dx.doi.org/10.1021/acscombsci.0c00099 |
work_keys_str_mv | AT ashrafizadehmilad progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT zarrabiali progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT hushmandikiavash progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT hashemifarid progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT rahmanimoghadamebrahim progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT raeimehdi progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT kalantarimahshad progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT tavakolshima progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT mohammadinejadreza progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT najafimasoud progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT tayfranklinr progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy AT makvandipooyan progressinnaturalcompoundssirnacodeliveryemployingnanovehiclesforcancertherapy |